BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™️ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A

BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™️ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A
Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL